Bristol-Myers Squibb Co. (BMY)

Statement of Financial Position, Assets
Quarterly Data

Difficulty: Beginner

Annual Data

Quarterly Data

The statement of financial position provides creditors, investors, and analysts with information on company's resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company's assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Bristol-Myers Squibb Co., Consolidated Statement of Financial Position, Assets (quarterly data)

USD $ in millions

		Jun 30, 2018		Mar 31, 2018		Dec 31, 2017		Sep 30, 2017		Jun 30, 2017		Mar 31, 2017		Dec 31, 2016		Sep 30, 2016		Jun 30, 2016		Mar 31, 2016		Dec 31, 2015		Sep 30, 2015		Jun 30, 2015		Mar 31, 2015		Dec 31, 2014		Sep 30, 2014		Jun 30, 2014		Mar 31, 2014		Dec 31, 2013		Sep 30, 2013		Jun 30, 2013		Mar 31, 2013
	Cash and cash equivalents
	Marketable securities
	Receivables
	Inventories
	Deferred income taxes
	Prepaid expenses and other
	Current assets
	Property, plant and equipment
	Goodwill
	Other intangible assets
	Deferred income taxes
	Marketable securities
	Other assets
	Noncurrent assets
	Total assets

Source: Bristol-Myers Squibb Co., Quarterly and Annual Reports

Item	Description	The company
Cash and cash equivalents	Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents.	Bristol-Myers Squibb Co.'s cash and cash equivalents declined from Q4 2017 to Q1 2018 and from Q1 2018 to Q2 2018.
Marketable securities	Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for less than one year or the normal operating cycle, whichever is longer.	Bristol-Myers Squibb Co.'s marketable securities increased from Q4 2017 to Q1 2018 but then declined significantly from Q1 2018 to Q2 2018.
Inventories	Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).	Bristol-Myers Squibb Co.'s inventories increased from Q4 2017 to Q1 2018 and from Q1 2018 to Q2 2018.
Current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Bristol-Myers Squibb Co.'s current assets declined from Q4 2017 to Q1 2018 and from Q1 2018 to Q2 2018.
Property, plant and equipment	Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, and production equipment.	Bristol-Myers Squibb Co.'s property, plant and equipment increased from Q4 2017 to Q1 2018 and from Q1 2018 to Q2 2018.
Noncurrent assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.	Bristol-Myers Squibb Co.'s noncurrent assets declined from Q4 2017 to Q1 2018 but then increased from Q1 2018 to Q2 2018 exceeding Q4 2017 level.
Total assets	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Bristol-Myers Squibb Co.'s total assets declined from Q4 2017 to Q1 2018 and from Q1 2018 to Q2 2018.

	Bristol-Myers Squibb Co.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

Bristol-Myers Squibb Co. (BMY)

Statement of Financial Position, AssetsQuarterly Data

Statement of Financial Position, Assets
Quarterly Data